KalVista Pharmaceuticals 소유권

주요 주주는 누구이며 내부자가 매수 또는 매도한 적이 있나요?

최근 내부자 거래

DB:4XC1 회사 또는 개인의 최근 내부자 거래
날짜	가치	이름	엔티티	공유	최대 가격
05 Nov 24	Buy€10,990,800	Frazier Life Sciences Management, LP	Company	1,200,000	€9.16
28 Mar 24	Sell€13,799,192	TCG Crossover Management, LLC	Company	1,355,014	€10.18
20 Feb 24	Buy€924,289	Frazier Life Sciences Management, LP	Company	65,573	€14.10
16 Feb 24	Sell€12,207,432	TCG Crossover Management, LLC	Company	877,125	€15.06
14 Feb 24	Sell€558,132	Christopher Yea	Individual	39,886	€13.99
14 Feb 24	Sell€394,202	Edward Feener	Individual	28,171	€13.99
14 Feb 24	Sell€816,585	Thomas Crockett	Individual	58,356	€13.99
14 Feb 24	Sell€571,691	Benjamin Palleiko	Individual	40,855	€13.99
08 Feb 24	Buy€1,168,523	VR Adviser, LLC	Company	86,048	€13.69
30 Jan 24	Buy€1,176,251	VR Adviser, LLC	Company	88,099	€13.35
25 Jan 24	Buy€82,574	VR Adviser, LLC	Company	7,030	€11.75
24 Jan 24	Buy€1,139,370	VR Adviser, LLC	Company	99,129	€11.52
19 Jan 24	Buy€1,655,492	VR Adviser, LLC	Company	143,605	€11.58
16 Jan 24	Buy€306,409	VR Adviser, LLC	Company	26,246	€11.69
10 Jan 24	Buy€1,575,047	VR Adviser, LLC	Company	137,700	€11.56
04 Jan 24	Buy€657,496	VR Adviser, LLC	Company	59,369	€11.13
29 Dec 23	Buy€5,849,474	VR Adviser, LLC	Company	519,017	€11.31
12 Dec 23	Buy€2,754,410	Frazier Life Sciences Management, LP	Company	343,435	€8.84

내부자 거래량

내부자 구매: 내부자가 지난 3개월 동안 판매한 것보다 더 많은 주식을 구입했는지 판단하기에는 데이터가 부족합니다.

소유권 분석

4XC1 의 소유 구조는 어떻게 되나요?
소유자 유형	공유 수	소유권 비율
개인 내부자	734,838	1.44%
헤지 펀드	8,212,005	16.1%
VC/PE 기업	11,137,598	21.8%
교육기관	30,987,701	60.7%

주식의 희석: 지난 해 주주 수는 희석되었으며, 총 발행 주식 수 43.1% 만큼 증가했습니다.

최대 주주

상위 25 주주가 회사의 93.56%를 소유하고 있습니다.

소유권	이름	공유	현재 값	변경 %	포트폴리오 %
12.7%	VR Adviser, LLC	6,249,731	€59.7m	0%	2.93%
9.93%	Frazier Life Sciences Management, LP	4,887,867	€46.7m	32.5%	1.91%
8.78%	Tang Capital Management, LLC	4,321,547	€41.3m	2.43%	3.13%
8.56%	Suvretta Capital Management, LLC	4,212,005	€40.3m	0.48%	1.5%
8.13%	Vestal Point Capital, LP	4,000,000	€38.2m	73.9%	3.18%
6.86%	Capital Research and Management Company	3,374,064	€32.3m	4.54%	데이터 없음
6.22%	BlackRock, Inc.	3,062,319	€29.3m	3.98%	데이터 없음
4.37%	The Vanguard Group, Inc.	2,150,527	€20.6m	8.03%	데이터 없음
3.23%	Tavistock Life Sciences	1,590,000	€15.2m	0%	1.0%
3.02%	Emerald Advisers, LLC	1,486,968	€14.2m	26.7%	0.3%
2.88%	Adage Capital Management, L.P.	1,419,792	€13.6m	-30.7%	0.02%
2.64%	Great Point Partners, LLC	1,299,503	€12.4m	-2.92%	4.57%
2.58%	State Street Global Advisors, Inc.	1,271,609	€12.2m	68.1%	데이터 없음
1.82%	BioImpact Capital LLC	896,915	€8.6m	1.7%	1.4%
1.69%	Geode Capital Management, LLC	830,984	€7.9m	3.07%	데이터 없음
1.47%	Dafna Capital Management, LLC	723,678	€6.9m	-10.3%	1.78%
1.24%	Woodline Partners LP	608,253	€5.8m	304%	0.05%
1.23%	Dimensional Fund Advisors LP	607,036	€5.8m	13.5%	데이터 없음
1.17%	Silverarc Capital Management, LLC	574,558	€5.5m	2.44%	1.31%
1.13%	Saturn V Capital Management LP	556,489	€5.3m	-50.7%	2.24%
0.88%	Schroder Investment Management Limited	431,232	€4.1m	-7.86%	데이터 없음
0.78%	Medical Strategy GmbH, Asset Management Arm	382,666	€3.7m	0%	0.22%
0.77%	Northern Trust Global Investments	379,375	€3.6m	14%	데이터 없음
0.76%	Jefferies Financial Group Inc.,Asset Management Arm	375,000	€3.6m	114%	0.18%
0.72%	First Turn Management, LLC	355,000	€3.4m	-66.5%	0.57%